Loading...
Market
Will AstraZeneca's FluMist nasal spray reach 1 million doses administered by end of Q1 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
AstraZeneca's official reports or press releases
Story
FDA Approves AstraZeneca's FluMist Nasal Spray, First Self-Administered Flu Vaccine
Sep 20, 2024, 08:06 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This marks the first time a flu vaccine can be administered at home without the need for a healthcare provider, making it the first of its kind. The vaccine, which is licensed for individuals aged 2 to 49, aims to increase accessibility and reduce barriers to flu vaccination. It will be available through third-party pharmacies, where users will complete a screening and eligibility assessment. The approval aligns with the FDA's broader efforts to expand consumer access to medications and reduce healthcare costs.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
Yes • 50%
No • 50%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Yes • 50%
No • 50%